In recent trading session, Galectin Therapeutics Inc (NASDAQ:GALT) saw 5.28 million shares changing hands at last check today with its beta currently measuring 0.78. Company’s recent per share price level of $0.82 trading at -$1.18 or -59.00% at last check today assigns it a market valuation of $51.09M. That most recent trading price of GALT’s stock is at a discount of -420.73% from its 52-week high price of $4.27 and is indicating a discount of -89.02% from its 52-week low price of $1.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.91 million shares which gives us an average trading volume of 293.02K if we extend that period to 3-months.
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
Upright in the red during last session for losing -59.00%, in the last five days GALT remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $0.82 price level, adding 65.25% to its value on the day. Galectin Therapeutics Inc’s shares saw a change of -50.60% in year-to-date performance and have moved -61.14% in past 5-day. Galectin Therapeutics Inc (NASDAQ:GALT) showed a performance of -70.87% in past 30-days. Number of shares sold short was 5.52 million shares which calculate 42.37 days to cover the short interests.
Galectin Therapeutics Inc (GALT) estimates and forecasts
Statistics highlight that Galectin Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -61.50% of value to its shares in past 6 months, showing an annual growth rate of 1.35% while that of industry is 16.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -14.30% during past 5 years.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Insiders are in possession of 30.95% of company’s total shares while institution are holding 15.77 percent of that, with stock having share float percentage of 22.85%. Investors also watch the number of corporate investors in a company very closely, which is 15.77% institutions for Galectin Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at GALT for having 2.12 million shares of worth $4.78 million. And as of 2024-06-30, it was holding 3.4143 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 1.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.5232 of outstanding shares, having a total worth of $3.53 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 1.25 shares of worth $1.08 million or 1.99% of the total outstanding shares. The later fund manager was in possession of 670.16 shares on Sep 30, 2024, making its stake of worth around $0.58 million in the company or a holder of 1.07% of company’s stock.
